Sherman M S, Lazar E J, Eichacker P
Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10467.
J Allergy Clin Immunol. 1988 May;81(5 Pt 1):908-11. doi: 10.1016/0091-6749(88)90949-9.
We evaluated the effect of glucagon on eight patients with asthma. After withholding bronchodilators for 12 hours, patients received either 2 units of intravenous glucagon or 2 ml of saline after a double-blind crossover protocol. Glucagon significantly improved the FEV1 (17.5% +/- 5.5 SEM) and the peak expiratory flow rate (14.2% +/- 4.9), compared to placebo (-2.4% +/- 2.9, p less than 0.02; 4.5% +/- 4.1, p less than 0.25, respectively). Seven patients had an excellent response to glucagon (40% to 105% of the response to inhaled isoproterenol), but four patients had no significant response. We conclude that glucagon, through its pharmacologic actions, can have a bronchodilator effect in selected patients with asthma.
我们评估了胰高血糖素对8例哮喘患者的影响。在停用支气管扩张剂12小时后，按照双盲交叉方案，患者分别接受2单位静脉注射胰高血糖素或2毫升生理盐水。与安慰剂相比（分别为-2.4%±2.9，p<0.02；4.5%±4.1，p<0.25），胰高血糖素显著改善了第一秒用力呼气容积（FEV1）（17.5%±5.5标准误）和呼气峰值流速（14.2%±4.9）。7例患者对胰高血糖素反应良好（为吸入异丙肾上腺素反应的40%至105%），但4例患者无明显反应。我们得出结论，胰高血糖素通过其药理作用，可对部分哮喘患者产生支气管扩张作用。
